NCT00064051View on ClinicalTrials.gov

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2003

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2008

Conditions
Pancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

DRUG

triapine

Trial Locations (7)

37203

Sarah Cannon Cancer Center at Centennial Medical Center, Nashville

46202

Indiana Oncology Hematology Consultants, Indianapolis

55455

University of Minnesota Cancer Center, Minneapolis

60637-1470

University of Chicago Cancer Research Center, Chicago

B-9000

Universitair Ziekenhuis Gent, Ghent

M20 4BX

Christie Hospital N.H.S. Trust, Manchester

SM2 5PT

Royal Marsden NHS Foundation Trust - Surrey, Sutton

Sponsors
All Listed Sponsors
lead

Vion Pharmaceuticals

INDUSTRY

NCT00064051 - 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter